Shanghai Minhang R&D Site
Here is Porton’s largest R&D center, designed to provide customers with DS to DP R&D services.
No.188, Beidou Road, Minhang District, Shanghai, China
15+Years
The R&D center team was established in 2007 and has a wealth of project experience.
2Buildings
Major departments include the Small Molecule Process Development Department, the Analytical Development Department, as well as the Kilogram Laboratory, and the Safety Laboratory
22,000m2Area
Porton's Technology Platform and Macromolecule Synthesis R&D Center are also located here.
Services
Small Molecular
Tides
Small Molecular
Porton offers efficient, flexible, and high-quality solutions for custom development and production of small molecule APIs, as well as technical services throughout the entire lifecycle from pre-clinical to commercial stages to our worldwide partners.
Tides
With five major R&D platforms, including peptides, oligonucleotides, conjugated drugs, high-performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.
Technology Platform
Porton's new technology platform focuses on providing advanced and green chemical technology solutions, dedicated to accelerating drug research, development, and production processes. Our platform encompasses a wide range of capabilities, including Crystallization, Bio-catalysis, Flow Chemistry, Catalyst High-throughput Screening, and Photochemistry, etc.
High Potency R&D Facilities
Our 500㎡ high-potency laboratory is designed to meet OEB 5 (OEL < 0.05 µg/m³) standards. Our facility boasts 8 isolators, 3 advanced purification units, and 4 lyophilizers. This exceptional setup ensures optimal conditions for the research and development of HPAPI.
One Porton One Quality
Compliance standards, Continuous improvement, Customer oriented
Quality management runs throughout the entire process of the drug life cycle. The quality management system of the drug product site is built in accordance with international standards and continues to adhere to the quality concept of 'more well-established system, more controllable quality.' This ensures that the GMP activities of the drug product site meet the requirements of international quality management systems and market drug regulatory agencies, including those of China, the European Union, FDA, and other mainstream regulations.
News
MoreNews2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
More
News2024-12-19
Porton Newsletter | Q4 2024 Recap
More
News2024-12-06
Porton Recognized as an Exemplary Case for Sustainable Development
More
News2024-12-06
Porton is thrilled to announce the launch of its newly redesigned official website
More
News2024-10-14
Driving innovation and excellence in the CDMO industry, Porton at 2024 CPHI Europe
More
